Overview

Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus

Status:
Unknown status
Trial end date:
2020-02-28
Target enrollment:
Participant gender:
Summary
To compare the effect of dapagliflozin combined with CSII and CSII alone on glucose profile in newly diagnosed type 2 diabetes mellitus by continuous glucose monitoring system.
Phase:
Phase 4
Details
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University
Treatments:
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Dapagliflozin
Insulin
Insulin Aspart
Insulin, Globin Zinc